• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Evaluation of anti-atherosclerotic effects of Sitagliptin via modulation of the mTOR pathway in male rabbits
This study aimed to investigate the effect of Sitagliptin on the progression of atherosclerosis. Twenty-one male New Zealand White rabbits weighing 2-2.5 kg each were split into three groups: normal control, atherogenic control, and Sitagliptin-treated. The following parameters: serum triglycerides (TG), total cholesterol (TC), LDL, and a tissue autophagy marker (p62) using ELISA, aortic mRNA expression of mTORC1 marker using Real-Time Quantitative PCR(RT-qPCR), and histological inspection of the aorta were assessed. The mRNA expression of mTORC1 and the lipid profile of aortic tissue are considerably elevated in atherogen...
Source: Journal of Medicine and Life - May 11, 2023 Category: General Medicine Authors: Hussam Hamza Sahib Bassim Mohammad Najah Rayish Hadi Source Type: research

Letter to the Editor regarding “Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes diagnosed after metformin-triggered stroke-like episodes”
We read with interest the article by Murakami et al. about a 40 years-old male with mitochondrial encephalopathy, lactic acidosis, and stroke-like episode (MELAS) syndrome due to the variant m.3243A>G with a heteroplasmy rate of 27%, in whom metformin was suspected to have triggered a stroke-like episode (SLE), the phenotypic hallmark of MELAS.1 Metformin was replaced by sitagliptin and the patient was discharged in a stable condition after three weeks.1 The study is excellent, but has limitations that are objectionable and should be discussed.
Source: Journal of Stroke and Cerebrovascular Diseases - April 20, 2023 Category: Neurology Authors: Josef Finsterer Tags: Letter to the Editor Source Type: research

Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
CONCLUSIONSIn patients with T2DM and ASCVD, cluster analysis identified four clinically distinct groups. Further cardiovascular phenotyping is warranted to inform patient care and optimize clinical trial designs.
Source: Diabetes Care - October 29, 2021 Category: Endocrinology Source Type: research

Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance
Conclusions Metformin and sitagliptin were both effective in reducing fasting glucose and HbA1c levels in patients with recent TIA or minor ischaemic stroke and IGT. However, the reduction of glucose levels and sample size was relatively small. The clinical relevance, therefore, needs to be tempered. A phase III trial is needed to investigate whether medical treatment, compared with lifestyle intervention or a combination of both, not only improves glucose metabolism in IGT, but also leads to reduction of recurrent TIA or ischaemic stroke in these patients. Trial registration number NL3048.
Source: BMJ Open - September 16, 2021 Category: General Medicine Authors: Osei, E., Zandbergen, A., Brouwers, P. J. A. M., Mulder, L. J. M. M., Koudstaal, P., Lingsma, H., Dippel, D. W. J., den Hertog, H. Tags: Open access, Neurology Source Type: research

Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
AbstractPurpose of ReviewResults from cardiovascular (CV) outcome trials have revealed important insights into the CV safety and efficacy of glucose-lowering agents, including dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1RA).Recent FindingsAmong patients with T2DM, DPP-4i have no significant effect on risk of major adverse CV events (MACE: CV death, myocardial infarction, or stroke) with mixed results regarding risk for heart failure (HF). While sitagliptin and linagliptin have neutral effects on HF risk, saxagliptin significantly increases the risk of HF. The CV safety of ...
Source: Current Cardiology Reports - August 7, 2020 Category: Cardiology Source Type: research

Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial
ConclusionGlycated haemogobin exhibits a U ‐shaped association with cardiovascular outcomes in patients with T2D and atherosclerotic vascular disease, with nadir around 7%.Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT00790205.
Source: European Journal of Heart Failure - July 27, 2020 Category: Cardiology Authors: Finlay A. McAlister, Yinggan Zheng, Cynthia M. Westerhout, John B. Buse, Eberhard Standl, Darren K. McGuire, Frans Van de Werf, Jennifer B. Green, Paul W. Armstrong, Rury R. Holman, TECOS Study Group Tags: Research Article Source Type: research

Pages: 1  2  3  4  5  6